April 11, 2018
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Camras Vision closes $5.7 million in Series A financing
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Camras Vision has completed $5.7 million in Series A funding to support four clinical trials, including a U.S. pilot study to evaluate the efficacy of the Camras device for the treatment of refractory glaucoma, according to a press release.
The Camras device, which drains aqueous humor externally, is an investigational device not approved by the FDA.
The Series A equity funding was led by VCapital, InFocus Capital Partners and Triangle Venture Alliance.
“Our first-in-human trial overseas has been underway for the past 18 months and has shown encouraging preliminary results,” Camras CEO Ray Krauss said in the release. “Product refinements will continue as we move forward with additional clinical trial sites.”